Drug Approval | June 23, 2022
Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
Govt. has set a target to increase the number of JanAushadhi Kendras to 10,000 by March 2024
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
The technology was able to identify approximately 32 percent more adenomas than standard colonoscopy procedures
Subscribe To Our Newsletter & Stay Updated
